AR075235A1 - Derivados de indol como agentes anticancer. - Google Patents

Derivados de indol como agentes anticancer.

Info

Publication number
AR075235A1
AR075235A1 ARP100100298A ARP100100298A AR075235A1 AR 075235 A1 AR075235 A1 AR 075235A1 AR P100100298 A ARP100100298 A AR P100100298A AR P100100298 A ARP100100298 A AR P100100298A AR 075235 A1 AR075235 A1 AR 075235A1
Authority
AR
Argentina
Prior art keywords
indol
derivatives
anticancer agents
hydroxyalkyl
cancer
Prior art date
Application number
ARP100100298A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR075235A1 publication Critical patent/AR075235A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso para el tratamiento del cáncer, así como composiciones farmacéuticas para el tratamiento de cáncer, así como composiciones farmacéuticas que comprenden dichos compuestos de la formula (1) y el proceso de preparacion. Reivindicacion 1: Un compuesto de la formula (1) incluyendo cualquiera de sus formas estereoquímicamente isoméricas, en donde R1es hidroxialquilo C1-6 o alquenilo C2-6; siempre que el sustituyente R1 esté ubicado en la posicion 6 o 7 del resto indol; R2 es hidrogeno o alquilo C1-4; Z es un radical seleccionado de las formulas (2) o (3); R3 es hidrogeno o hidroxialquilo C1-4; R4 es hidroxi o alquiloxi C1-4; R5 H o alquilo C1-4; o R4 y R5 se toman juntos para formar oxo; una de sus sales farmacéuticamente aceptables o uno de sus solvatos.
ARP100100298A 2009-02-04 2010-02-03 Derivados de indol como agentes anticancer. AR075235A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09152089 2009-02-04

Publications (1)

Publication Number Publication Date
AR075235A1 true AR075235A1 (es) 2011-03-16

Family

ID=40738626

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100298A AR075235A1 (es) 2009-02-04 2010-02-03 Derivados de indol como agentes anticancer.

Country Status (23)

Country Link
US (1) US8541442B2 (es)
EP (1) EP2393801B1 (es)
JP (1) JP5612611B2 (es)
KR (1) KR101730407B1 (es)
CN (1) CN102307868B (es)
AR (1) AR075235A1 (es)
AU (1) AU2010210178B2 (es)
BR (1) BRPI1008855B8 (es)
CA (1) CA2749209C (es)
CL (1) CL2011001860A1 (es)
CO (1) CO6341625A2 (es)
EA (1) EA021883B1 (es)
ES (1) ES2639752T3 (es)
IL (1) IL214427A (es)
MX (1) MX2011008195A (es)
MY (1) MY152018A (es)
NO (1) NO20111199A1 (es)
NZ (1) NZ594186A (es)
SG (1) SG173495A1 (es)
TW (1) TWI476189B (es)
UA (1) UA107455C2 (es)
WO (1) WO2010089327A2 (es)
ZA (1) ZA201105695B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771341A4 (en) * 2011-10-28 2015-09-23 Univ Texas NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
CN108239083B (zh) 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
CN106632303A (zh) * 2017-01-09 2017-05-10 湖南华腾制药有限公司 一种6‑噻唑基吲哚衍生物的制备方法
JP2021503498A (ja) 2017-11-20 2021-02-12 アリアジェン，インコーポレイテッド アリール炭化水素受容体（ａｈｒ）調節剤としてのインドール化合物
CN108659003B (zh) * 2018-04-14 2021-01-26 上海朝晖药业有限公司 一种治疗口腔溃疡的化合物的制备方法
WO2020214740A1 (en) 2019-04-15 2020-10-22 Ariagen, Inc. Chiral indole compounds and their use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
AUPO863197A0 (en) 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
US6309492B1 (en) 1998-09-16 2001-10-30 Marc A. Seidner Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
KR20010086073A (ko) 1998-12-02 2001-09-07 데이비드 존 우드 ｐ53계 단백질의 배좌 안정성을 회복하기 위한 방법 및조성물
WO2001042224A1 (en) 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
US6835731B2 (en) 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
EP1379239B1 (en) * 2001-03-29 2007-09-12 Eli Lilly And Company N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
AU2002357728A1 (en) 2001-11-09 2003-05-19 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
HUP0402003A3 (en) 2001-11-13 2005-06-28 Dimensional Pharm Inc Substituted 1,4-benzodiazepines, pharmaceutical compositions containing them and uses thereof
CN100486969C (zh) 2001-12-18 2009-05-13 霍夫曼-拉罗奇有限公司 顺式-2,4,5-三苯基-咪唑啉及其在肿瘤治疗中的应用
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
SI1809622T1 (sl) * 2004-09-22 2010-11-30 Janssen Pharmaceutica Nv Inhibitorji interakcije med MDM in P
CA2644643C (en) 2006-03-22 2015-05-19 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
ATE470665T1 (de) 2006-03-22 2010-06-15 Janssen Pharmaceutica Nv Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
US20100129933A1 (en) * 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
EP2185541B1 (en) * 2007-08-06 2015-01-28 Janssen Pharmaceutica, N.V. Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53
ATE547415T1 (de) 2007-09-21 2012-03-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53

Also Published As

Publication number Publication date
CL2011001860A1 (es) 2012-07-20
EP2393801B1 (en) 2017-07-12
MY152018A (en) 2014-08-15
UA107455C2 (uk) 2015-01-12
WO2010089327A3 (en) 2010-10-21
JP5612611B2 (ja) 2014-10-22
KR20110116195A (ko) 2011-10-25
US8541442B2 (en) 2013-09-24
IL214427A0 (en) 2011-09-27
ES2639752T3 (es) 2017-10-30
KR101730407B1 (ko) 2017-04-26
CA2749209C (en) 2017-01-10
TW201038552A (en) 2010-11-01
CN102307868A (zh) 2012-01-04
BRPI1008855A2 (pt) 2016-03-15
TWI476189B (zh) 2015-03-11
NO20111199A1 (no) 2011-11-04
ZA201105695B (en) 2014-01-29
US20110294846A1 (en) 2011-12-01
BRPI1008855B1 (pt) 2020-05-12
NZ594186A (en) 2012-12-21
MX2011008195A (es) 2011-09-06
CA2749209A1 (en) 2010-08-12
WO2010089327A2 (en) 2010-08-12
EA201170997A1 (ru) 2012-01-30
JP2012516872A (ja) 2012-07-26
EA021883B1 (ru) 2015-09-30
AU2010210178B2 (en) 2014-06-05
BRPI1008855B8 (pt) 2021-05-25
CN102307868B (zh) 2016-06-22
AU2010210178A1 (en) 2011-07-28
EP2393801A2 (en) 2011-12-14
SG173495A1 (en) 2011-09-29
CO6341625A2 (es) 2011-11-21
IL214427A (en) 2016-02-29

Similar Documents

Publication Publication Date Title
AR075235A1 (es) Derivados de indol como agentes anticancer.
AR082826A2 (es) Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
CR10712A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales
ECSP088114A (es) Nuevos derivados de la 2-azetidinona y su uso como inhibidores de absorción del colesterol para el tratamiento de hiperlipidemia
UY29702A1 (es) Inhibidores macrocíclicos del virus de hepatitis c
CO7400872A2 (es) Derivados sustituidos de ftalazin-1(2h)-ona
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
CO6251271A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
AR087182A1 (es) DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
CU20110145A7 (es) Derivados de sulfonamida
ECSP078053A (es) Nuevos derivados de 2-azetidinona útiles en el tratamiento de condiciones de hiperlipidemia
CL2012000925A1 (es) Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras.
AR077999A1 (es) Antagonistas de pirimidin y triazin-hepcidina
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
AR078722A1 (es) Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol
AR090955A1 (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del vih
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer
AR076263A1 (es) Composiciones y metodos para tratar cancer. uso.
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
AR060427A1 (es) Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovasculares
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure